BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
Joseph P. Erinjeri, Gabriel C. Fine, Gosse J. Adema, Muneeb Ahmed, Julius Chapiro, Martijn den Brok, Rafael Duran, Stephen J. Hunt, D. Thor Johnson, Jens Ricke, Daniel Y. Sze, Beau Bosko Toskich, Bradford J. Wood, David Woodrum, S. Nahum Goldberg. Immunotherapy and the Interventional Oncologist: Challenges and Opportunities—A Society of Interventional Oncology White PaperRadiology 2019; 292(1): 25 doi: 10.1148/radiol.2019182326
Min Ding, Ying Wang, Jiachang Chi, Tao Wang, Xiaoyin Tang, Dan Cui, Qijun Qian, Bo Zhai, Beicheng Sun. Is Adjuvant Cellular Immunotherapy Essential after TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma? A Systematic Meta-Analysis of Studies Including 1774 PatientsPLOS ONE 2016; 11(12): e0168798 doi: 10.1371/journal.pone.0168798
David Stillström, Marie Beermann, Jennie Engstrand, Jacob Freedman, Henrik Nilsson. Initial experience with irreversible electroporation of liver tumoursEuropean Journal of Radiology Open 2019; 6: 62 doi: 10.1016/j.ejro.2019.01.004
Xiaojing Ren, Yuanyuan Ji, Xuhua Jiang, Xun Qi. Down-regulation of siglec-2 (CD22) predicts worse overall survival from HBV-related early-stage hepatocellular carcinoma: a preliminary analysis from Gene Expression OmnibusBioscience Reports 2018; 38(6) doi: 10.1042/BSR20181423
Jasmine Sinha, Neil Mehta, Jennifer L. Dodge, Eduard Poltavskiy, John Roberts, Francis Yao. Are There Upper Limits in Tumor Burden for Down‐Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All‐Comers ProtocolHepatology 2019; 70(4): 1185 doi: 10.1002/hep.30570
Chinthalapally V. Rao, Adam S. Asch, Hiroshi Y. Yamada. Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancerCarcinogenesis 2017; 38(1): 2 doi: 10.1093/carcin/bgw118
Chenwei Pan, Luxia Xiang, Zhenzhen Pan, Xiaodong Wang, Jie Li, Lu Zhuge, Peipei Fang, Qipeng Xie, Xuezhen Hu. MiR-544 promotes immune escape through downregulation of NCR1/NKp46 via targeting RUNX3 in liver cancerCancer Cell International 2018; 18(1) doi: 10.1186/s12935-018-0542-y
Dimitrios N Samonakis, Elias A Kouroumalis. Systemic treatment for hepatocellular carcinoma: Still unmet expectationsWorld Journal of Hepatology 2017; 9(2): 80-90 doi: 10.4254/wjh.v9.i2.80
Yang Chen, Chang-Yong E, Zhi-Wen Gong, Shui Liu, Zhen-Xiao Wang, Yong-Sheng Yang, Xue-Wen Zhang. Chimeric antigen receptor-engineered T-cell therapy for liver cancerHepatobiliary & Pancreatic Diseases International 2018; 17(4): 301 doi: 10.1016/j.hbpd.2018.05.005
V. V. Breder, M. U. Pitkevich, E. R. Virshke, L. A. Kostyakova, I. A. Dzhanyan, K. K. Laktionov. BCLC-B hepatocellular carcinoma treatment or when should the systemic therapy be startedMedical Council 2018; (10): 27 doi: 10.21518/2079-701X-2018-10-27-32
Hongchi Yu, Yang Shen, Jingsi Jin, Yingying Zhang, Tang Feng, Xiaoheng Liu. Fluid shear stress regulates HepG2 cell migration though time-dependent integrin signaling cascadeCell Adhesion & Migration 2018; 12(1): 56 doi: 10.1080/19336918.2017.1319042
Mostafa MM El-Miligy, Samia M Rida, Fawzia A Ashour, Mona H Badr, Ehab M El-Bassiony, Maha A El-Demellawy, Ashraf M Omar. Dual inhibitors of hepatitis C virus and hepatocellular carcinoma: design, synthesis and docking studiesFuture Science OA 2018; 4(1): FSO252 doi: 10.4155/fsoa-2017-0075
K. Okrah, S. Tarighat, B. Liu, H. Koeppen, M. C. Wagle, G. Cheng, C. Sun, A. Dey, M. T. Chang, T. Sumiyoshi, Z. Mounir, C. Cummings, G. Hampton, L. Amler, J. Fridlyand, P. S. Hegde, S. J. Turley, M. R. Lackner, S. M. Huang. Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biologynpj Precision Oncology 2018; 2(1) doi: 10.1038/s41698-018-0068-8
Qing Zhang, Xiang‐Fei Yuan, Yang Lu, Zhen‐Zhen Li, Shi‐Qi Bao, Xiao‐Long Zhang, Yuan‐Yuan Yang, Dong‐Mei Fan, Yi‐Zhi Zhang, Chen‐Xuan Wu, Hong‐Xing Guo, Yan‐Jun Zhang, Zhou Ye, Dong‐Sheng Xiong. Surface expression of anti‐CD3scfv stimulates locoregional immunotherapy against hepatocellular carcinoma depending on the E1A‐engineered human umbilical cord mesenchymal stem cellsInternational Journal of Cancer 2017; 141(7): 1445 doi: 10.1002/ijc.30846
Francesco Paolo Russo, Angela Imondi, Erica Nicola Lynch, Fabio Farinati. When and how should we perform a biopsy for HCC in patients with liver cirrhosis in 2018? A reviewDigestive and Liver Disease 2018; 50(7): 640 doi: 10.1016/j.dld.2018.03.014
Samantha A. Armstrong, Aiwu Ruth He. Immuno-oncology for Hepatocellular CarcinomaClinics in Liver Disease 2020; 24(4): 739 doi: 10.1016/j.cld.2020.07.007
Katharina Leuchte, Elena Staib, Martin Thelen, Philipp Gödel, Axel Lechner, Peter Zentis, Maria Garcia-Marquez, Dirk Waldschmidt, Rabi Raj Datta, Roger Wahba, Christian Wybranski, Thomas Zander, Alexander Quaas, Uta Drebber, Dirk Ludger Stippel, Christiane Bruns, Michael von Bergwelt-Baildon, Kerstin Wennhold, Hans Anton Schlößer. Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinomaCancer Immunology, Immunotherapy 2020;  doi: 10.1007/s00262-020-02734-1
Kangwei Wang, Xin Nie, Zhuona Rong, Tingting Fan, Juan Li, Xinxin Wang, Huiling Li, Jianyi Dong, Jun Chen, Fujin Wang, Jingyu Wang, Aiguo Wang. B lymphocytes repress hepatic tumorigenesis but not development in Hras12V transgenic miceInternational Journal of Cancer 2017; 141(6): 1201 doi: 10.1002/ijc.30823
Yen‐Hao Erik Lai, Robert Morhard, Nirmala Ramanujam, Michael W. Nolan. Minimally invasive ethyl cellulose ethanol ablation in domesticated cats with naturally occurring head and neck cancers: Six catsVeterinary and Comparative Oncology 2021;  doi: 10.1111/vco.12687
Josefa A. Rodríguez. HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activationOncology Letters 2017; 14(4): 4415 doi: 10.3892/ol.2017.6784
Vito Longo, Antonio Gnoni, Andrea Casadei Gardini, Salvatore Pisconti, Antonella Licchetta, Mario Scartozzi, Riccardo Memeo, Vincenzo Ostilio Palmieri, Giuseppe Aprile, Daniele Santini, Patrizia Nardulli, Nicola Silvestris, Oronzo Brunetti. Immunotherapeutic approaches for hepatocellular carcinomaOncotarget 2017; 8(20): 33897 doi: 10.18632/oncotarget.15406
Junjie Kong, Tao Wang, Shu Shen, Zifei Zhang, Xianwei Yang, Wentao Wang. A genomic-clinical nomogram predicting recurrence-free survival for patients diagnosed with hepatocellular carcinomaPeerJ 2019; 7: e7942 doi: 10.7717/peerj.7942
J. Mittler, H. Lang. Entwicklungen der Immunmodulation nach Transplantation im Hinblick auf De-novo-Malignome und TumorrezidiveDer Onkologe 2016; 22(7): 461 doi: 10.1007/s00761-016-0051-3
Hendrik Reynaert, Isabelle Colle. Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the LiteratureInternational Journal of Molecular Sciences 2019; 20(19): 4811 doi: 10.3390/ijms20194811
Ruwanthi Kolamunnage-Dona, Adina Najwa Kamarudin. Adjustment for the measurement error in evaluating biomarker performances at baseline for future survival outcomes: Time-dependent receiver operating characteristic curve within a joint modelling frameworkResearch Methods in Medicine & Health Sciences 2021; 2(2): 51 doi: 10.1177/2632084320972257
David Stillström, Raluca-Maria Sandu, Jacob Freedman. Accuracy of Electrode Placement in IRE Treatment with Navigated GuidanceCardioVascular and Interventional Radiology 2021;  doi: 10.1007/s00270-020-02762-5
Jian-Wang Li, Chun-Zhen Huang, Jian-Hua Li, Jian-Hua Yuan, Qiong-Hui Chen, Wei-Fang Zhang, Zhen-Sheng Xu, Ying-Ping Liu, Yong Li, Mei-Xiao Zhan, Li-Gong Lu. Six2 is negatively correlated with good prognosis and decreases 5-FU sensitivity via suppressing E-cadherin expression in hepatocellular carcinoma cellsBiomedicine & Pharmacotherapy 2018; 104: 204 doi: 10.1016/j.biopha.2018.05.032